In the last years, the therapeutic potential of several mutated IDH1/2 (mIDH1/2) inhibitors has been intensively investigated to counteract this neomorphic activity and reduce D2HG levels in tumours [14]. The gene discussed is IDH1; the disease is neoplasm.